Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Honore, Patrick M.
Barreto Gutierrez, Leonel
De Bels, David
Text and Data Mining valid from 2020-10-09
Version of Record valid from 2020-10-09
29 August 2020
15 September 2020
9 October 2020
Ethics approval and consent to participate
The authors declare to have no competing interests.